These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9436582)

  • 1. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.
    Jackson MR; Danby CA; Alving BM
    Ann Thorac Surg; 1997 Dec; 64(6):1815-7. PubMed ID: 9436582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP; Smith K; Braden GA; Owen J
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of heparin-induced thrombocytopenia.
    Peters FP
    J Thorac Cardiovasc Surg; 1997 Sep; 114(3):517-8. PubMed ID: 9305220
    [No Abstract]   [Full Text] [Related]  

  • 4. Coronary artery bypass grafting in a patient with type II heparin associated thrombopenia.
    Christiansen S; Geiger A; Splittgerber FH; Reidemeister JC
    Cardiovasc Surg; 1998 Feb; 6(1):90-3. PubMed ID: 9546852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.
    Ortel TL; Gockerman JP; Califf RM; McCann RL; O'Connor CM; Metzler DM; Greenberg CS
    Thromb Haemost; 1992 Mar; 67(3):292-6. PubMed ID: 1379384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
    Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
    Olin DA; Urdaneta F; Lobato EB
    J Cardiothorac Vasc Anesth; 2000 Dec; 14(6):707-9. PubMed ID: 11139115
    [No Abstract]   [Full Text] [Related]  

  • 8. Heparin-induced thrombocytopenia and antithrombotic therapy.
    Boon DM; Michiels JJ; Stibbe J; van Vliet HH; Kappers-Klunne MC
    Lancet; 1994 Nov; 344(8932):1296. PubMed ID: 7526097
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.
    Kanagasabay R; Unsworth-White MJ; Farnsworth G; Haxby EJ; Smith EE
    J Thorac Cardiovasc Surg; 2000 Aug; 120(2):428-9. PubMed ID: 10917979
    [No Abstract]   [Full Text] [Related]  

  • 10. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
    Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
    Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
    Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
    Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes.
    Rice L; Nguyen PH; Vann AR
    Postgrad Med; 2002 Sep; 112(3):85-9. PubMed ID: 12360660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E; Bauersachs R
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Options to heparin anticoagulation for cardiac interventions.
    Kahn JK
    Catheter Cardiovasc Interv; 1999 Mar; 46(3):356. PubMed ID: 10348140
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis.
    Rowlings PA; Mansberg R; Rozenberg MC; Evans S; Murray B
    Aust N Z J Med; 1991 Feb; 21(1):52-4. PubMed ID: 1709804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
    Cantor WJ; Leblanc K; Garvey B; Watson KR; Rasymas A; Strauss BH
    Catheter Cardiovasc Interv; 1999 Mar; 46(3):352-5. PubMed ID: 10348139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
    Burkhard-Meier U; Söhngen D; Schultheiss HP; Greinacher A; Schwartzkopff B; Vogt M; Heyll A; Schneider W
    Intensive Care Med; 1995 Jun; 21(6):542-3. PubMed ID: 7560499
    [No Abstract]   [Full Text] [Related]  

  • 18. Heparin-induced thrombocytopenia: pathophysiology and management.
    Mureebe L; Silver D
    Vasc Endovascular Surg; 2002; 36(3):163-70. PubMed ID: 12075381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.
    Lubenow N; Greinacher A
    J Thromb Thrombolysis; 2000 Nov; 10 Suppl 1():47-57. PubMed ID: 11155194
    [No Abstract]   [Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O; Ranze P; Magnani HN; Greinacher A
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.